Background: Gastrointestinal stromal tumors (GISTs) are rare neoplasms that arise from the mesenchymal tissues in the gastrointestinal tract. The appendicial location of such a tumor is more rare, with only a few cases reported in this site to date.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract with an incidence of less than 1%. They are mesenchymal tumors that arise from the neoplastic transformation of intestinal pacemaker cells (intestinal cells of Cajal or their stem cell precursors) that express the c-KIT proto-oncogene. [1, 2] The tumors arise in the stomach in 40-70% of cases and in the small intestine in 20-40% of cases, while less than 10% of tumors occur in the esophagus, colon or rectum; they usually present in adults over 40 years of age, with a peak incidence in the sixth and seventh decades of life. [3] This tumor is extremely rare in the appendix with only few cases found in this location to date. [4] They may also originate from extragastrointestinal tract sites such as the omentum, mesentery, retroperitoneum, pancreas, fallopian tubes or uterus. [4, 5] Most GISTs are asymptomatic at the initial stage. Although still relatively uncommon, prompt recognition, accurate diagnosis and early intervention are critical in this potentially surgically curable disease.
CASE REPORT
A 52-year-old female was admitted on account of recurrent right-sided lower abdominal pain of 4 years duration. The pain was dull, constant and non-radiating. There was an episode of diarrhea; however, there was no history of fever, nausea, anorexia, vomiting, weight loss or gastrointestinal tract bleeding. General examination was normal. Abdominal examination revealed a full abdomen that moves with respiration, soft and no palpable mass. There was right ileac fossa tenderness with associated positive psoas and Rovsing's sign. The abdomino-pelvic ultrasonograph revealed features of sub-acute appendicitis. Other laboratory investigations were within normal limits.
Intra-operatively, the abdominal cavity showed clear peritoneal fluid and multiple mesenteric lymph nodes along the ileocolic and appendiceal vessels. Grossly, the appendix measured 9 × 2 × 1 cm (in its widest dimensions) and weighed 4.0 g. The serosal surface was smooth and shiny and the cut surfaces showed a lumen narrowed by solid grey tumor that measured 2 cm in its widest diameter [ Figure 1 ]. There were seven lymph nodes aggregating to 8 × 5 cm and the cut surfaces showed solid grey areas. Sections of the vermiform appendix showed a mesenchymal tumor growing in fascicles and in sheets composed of spindle cells having plump regular nuclei and moderate amount of amphophilic cytoplasm. The stroma is moderate and hyalinized and mitotic activity is infrequent [ Figure 2 ]. The tumor is immunohistochemically positive to c-KIT [ Figure 3 ] and CD34 but negative for smooth muscle actin antibodies. Sections of the lymph nodes shows effacement of the nodal architecture by the tumor described above.
Imatinib at a daily dose of 400 mg for 4 weeks post-operatively was prescribed. However, the patient is yet to procure the prescribed drug on account of financial constraints. She was discharged and followed-up at 1 month. Follow-up evaluation plan included an ultrasound scan that was normal at 4 weeks post-operation.
DISCUSSION
GIST is the most common mesenchymal tumor in the gastrointestinal tract. It used to be a collective term referring to primary mesenchymal tumors of the gastrointestinal tract. However, it is now considered to be a particular tumor that originates from the interstitial cell of Cajal, or its precursor in the GIT, and therefore has expression of the tyrosine kinase receptor KIT in most cases. [1] Among the appendiceal mesenchymal tumors, leiomyoma is the most common tumor reported. Other tumors include leiomyosarcoma, gastrointestinal stromal tumor, Kaposi's sarcoma, granular cell tumor, gangliocytic paraganglioma, Schwannoma, lipoma, hemangioma and neural tumors. [1, 4, 6] GISTs can be histologically spindled, epithelioid or occasionally pleomorphic. Their most distinctive feature is expression of KIT (CD117), the stem cell/mast cell growth factor receptor. [1, 4] Ligand-independent activation of KIT by gain-of-function mutations is believed to be pathogenetically important in a majority of GISTs. [3] The identification of GISTs has recently gained new importance because a KIT tyrosine kinase inhibitor drug STI571 is available that has shown promise in the treatment of metastatic GIST. [6] Our patient is a middle aged woman, which is in contrast to most previous reports of appendiceal GIST in which the patients are middle-aged and older adults men. [2, 4] However, Yap et al. [7] in Singapore have also reported a case in a middle aged woman. The relationship of appendiceal GISTs to symptoms is difficult to determine because a significant proportion of cases were incidental findings at autopsy and major surgery or are negative for inflammation, which could have caused the appendicitis-like symptoms. [4] Our patient presented with recurrent right-sided lower abdominal pain. This is similar to the presentation seen in other African patients. [4, 5] No single laboratory test (other than histology) can specifically confirm or rule out the presence of GIST, [8, 9] as in our case there was no laboratory evidence but abdomino-pelvic ultrasonograph revealed features suggestive of subacute appendicitis. It is generally accepted that tumors greater than 5 cm have a higher risk of metastasis or recurrence. [9, 10] The tumor in our case measures 2 cm in its widest diameter. Histologically, our case lacks evidence of malignancy, for example absence of mitotic activity and necrosis. A mitotic count greater than 5 mitoses per 50 HPF is considered to be associated with malignant behavior, which is in contrast to most GISTs of the small intestine and colon. [10] The tumor was immunohistochemically positive for c-KIT and CD34 and negative for smooth muscle actin. C-KIT positivity is now the best defining immunohistochemical feature of GISTs. [3] [4] [5] [6] Radiotherapy and conventional chemotherapy are known to be ineffective in the management of GISTs. Imatinib, a tyrosine kinase inhibitor, antagonizes the effects of the KIT and PDGFRA proteins and has revolutionized the treatment of advanced and unresectable GISTs. [5] Recent studies indicate that responsiveness to Imatinib and other tyrosine kinase inhibitors is dependent on the type and site of mutation, with deletions appearing to be more aggressive than point mutations and exon 9 mutations being less responsive to Imanitib therapy than exon 11 lesions. [5, 10] Lack of molecular assessment for mutation and deletions in exons 9 or 11, and the financial constraint in our patient, are important limitations. However, other factors that independently predict shorter progression-free survival for patients treated with Imatinib as first-line therapy include male sex, low hemoglobin, high neutrophil count, poor performance status and serum protein level. [9] In this regard, our patient has good prognostic potentials (female gender, good performance status and normal laboratory parameters).
CONCLUSION
Multitudes of diagnostic and therapeutic difficulties make the management of appendiceal GIST very challenging in a resource-poor setting such as ours, and follow-up of the patient is suggested given the fact that histologic parameters may not accurately predict the behavior of GIST.
